Sign inCreate account

Report workspace tools

NCT01263223COMPLETEDanonymous

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors

Sponsor

Source record

Eli Lilly and Company

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

LY2216684, Placebo

Indication / condition

AI-normalized

Major Depressive Disorder

Intervention

Source record

LY2216684, Placebo

Source & freshness

Source record

NCT ID

NCT01263223

Original source

ClinicalTrials.gov

Source last updated

Oct 23, 2018

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01263223

Title

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors

Sponsor

Eli Lilly and Company

Status

COMPLETED

Phase

PHASE1

Condition raw

Major Depressive Disorder

Condition normalized

Major Depressive Disorder

Modality raw

major depressive disorder

Modality normalized

small molecule

Target raw

LY2216684, Placebo

Target normalized

LY2216684, Placebo

Interventions

LY2216684, Placebo

Public preview

Source record

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Major Depressive Disorder. SEO and diligence focus: LY2216684, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01263223

Status

COMPLETED

Phase

PHASE1

Sponsor

Eli Lilly and Company

Executive brief

Investment-Ready Snapshot

Effect of LY2216684 on Ambulatory Heart Rate and Blood Pressure in Patients With Major Depressive Disorder Who Are Being Treated With Selective Serotonin Reuptake Inhibitors is a PHASE1 clinical asset sponsored by Eli Lilly and Company in Major Depressive Disorder. SEO and diligence focus: LY2216684, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 23, 2018
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01263223

Indication

Major Depressive Disorder

Modality

small molecule

Target

LY2216684, Placebo

Intervention

LY2216684, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.